Capricor Therapeutics Inc (CAPR)vsJohnson & Johnson (JNJ)
CAPR
Capricor Therapeutics Inc
$33.58
+3.45%
HEALTHCARE · Cap: $2.04B
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 865647% more annual revenue ($96.36B vs $11.13M). JNJ leads profitability with a 21.8% profit margin vs 0.0%. CAPR appears more attractively valued with a PEG of 0.38. JNJ earns a higher WallStSmart Score of 59/100 (C).
CAPR
Avoid31
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+56.1%
Fair Value
$55.12
Current Price
$33.58
$21.54 discount
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
ROE of -46.6% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CAPR
The strongest argument for CAPR centers on PEG Ratio. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : CAPR
The primary concerns for CAPR are EPS Growth, Profit Margin, Operating Margin.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CAPR profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
CAPR carries more volatility with a beta of 0.48 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 31/100), backed by strong 21.8% margins. CAPR offers better value entry with a 56.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Capricor Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?